Biopharma manufacturer Repligen (NASDAQ:RGEN) exceeded revenue expectations in Q1 CY2025, reporting $169.2 million in sales. With full-year revenue guidance above estimates, the company's growth was driven by demand from large pharma, order growth, and market resilience.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing